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Toll-like receptors (TLRs) are key receptors of the innate immune system which are expressed on immune and nonimmune cells.
They are activated by both pathogen-associated molecular patterns and endogenous ligands. Activation of TLRs culminates in the
release of proinflammatory cytokines, chemokines, and apoptosis. Ischaemia and ischaemia/reperfusion (I/R) injury are associated
with significant inflammation and tissue damage. There is emerging evidence to suggest that TLRs are involved in mediating
ischaemia-induced damage in several organs. Critical limb ischaemia (CLI) is the most severe form of peripheral arterial disease
(PAD) and is associated with skeletal muscle damage and tissue loss; however its pathophysiology is poorly understood. This paper
will underline the evidence implicating TLRs in the pathophysiology of cerebral, renal, hepatic, myocardial, and skeletal muscle
ischaemia and I/R injury and discuss preliminary data that alludes to the potential role of TLRs in the pathophysiology of skeletal
muscle damage in CLI.
1. Introduction
Critical limb ischaemia (CLI) is the most severe form of
peripheral arterial disease (PAD). Whilst PAD describes
stenotic or aneurysmal disease in any arterial bed except
the coronary arteries, CLI generally describes advanced
atherosclerosis in the lower limb arteries leading to a
reduced blood supply to the tissues of the lower limb
resulting in rest pain and/or tissue loss. PAD affects 27
million people in Western Europe and North America, and
approximately 1-2% of these patients will develop CLI [1].
Further, CLI is associated with significant morbidity and
mortality: a large observational multicentre cohort study
of CLI patients observed a 6-month amputation rate of
12% and 1-year mortality rate of 19.1% [2]. However
despite the importance of this condition, management
of CLI patients continues to be challenging with limited
treatment modalities available. Surgical or endovascular
intervention remains the mainstay of therapy by improving
blood flow. However, even successful revascularisation is not
associated with an improvement in the functional ability
of patients with CLI [3], and most patients have persistent
or recurring symptoms requiring further treatment [4]. In
addition, a significant number of patients with CLI are not
suitable for revascularisation and treatment is limited to
pharmacological agents such as iloprost where outcomes
have been unsuccessful or inconsistent [5] or amputation.
Whilst work has been carried out on the aetiology of PAD the
downstream effects of reduced blood flow to the main organ,
that is, skeletal muscle are still poorly understood. A better
understanding of the pathophysiological processes occurring
within the skeletal muscle in CLI may enable us to identify
potential therapeutic targets. Recent studies on ischaemia
and ischaemia/reperfusion (I/R) injury of various organs
systems have identified the involvement of toll-like receptors
(TLRs) in the pathogenesis of hypoxic/ischaemic injury [6].
We aim to review this evidence for the role of TLRs in
ischaemia and ischaemia/reperfusion injury as well as discusss
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Table 1: Exogenous/endogenous ligands and antagonists of TLRs; n.d.: not discovered.
TLR Microbial ligands Endogenous ligands Antagonists
TLR1/TLR2 Triacyl lipopeptides (Pam3CSK4) n.d. n.d.
TLR2/TLR6
Diacyl lipopeptides (Pam2CSK4),
zymosan, porins, bacterial
peptidoglycan, LPSs of gram positive
bacteria
HSP-60, HSP-70, HMGB-1 n.d.
TLR3 Ds RNA mRNA n.d.
TLR4 LPS
HSP-22, HSP-60, HSP-70, HSP-96,
fibrinogen, HMGB-1, hyaluronan
fragments, fibronectin (extra domain A)
Eritoran (E5564, a lipid A derivative),
TAK-242
TLR5 Flagellin n.d. n.d.
TLR7 ssRNA (viral) ssRNA (immune complexes) CpG ODN, CpG 52364
TLR8 ssRNA (viral) ssRNA (immune complexes) CpG 52364
TLR9 DNA (bacterial/viral) DNA (immune complexes) CpG ODN, CpG 52364
TLR11 Toxoplasma gondii n.d. n.d.
TLR10, 12, 13 n.d. n.d. n.d.
the potential implication of TLRs in the pathophysiology of
skeletal muscle in CLI.
2. Toll-Like Receptors
Toll-like receptors are key receptors of the innate immune
system as they recognise and respond to components
of invading microorganisms termed pathogen-associated
molecular patterns (PAMPs). PAMPs consist of lipids,
lipopeptides, proteins, and nucleic acids [7], and upon
binding to TLRs they lead to the activation of the TLR
signalling pathway. This culminates in the release of various
cytokines, chemokines, and interferons that has implications
for both the innate and adaptive immune systems [8]. TLRs
are type 1 membrane glycoproteins that consist of a ligand-
binding external domain comprised of 19–25 leucine rich
repeat (LRR) motifs and a cytoplasmic signalling domain
that is termed the toll/interleukin 1 (TIR) domain. So
far 13 TLRs have been identified in mammals of which
eleven functional TLRs (TLR 1–11) have been discovered
in humans. These can be subdivided by their subcellular
localisation. TLR 1, 2, 4, 5, 6, and 10 are expressed on
the cell surface whereas TLR 3, 7, 8, and 9 are located in
the intracellular compartments, typically in the endosomes
and the endoplasmic reticulum [9]. Toll-like receptors are
expressed on both immune and nonimmune cells such as
macrophages [10], neutrophils [10], B cells [11] as well as
epithelial cells [12], myocytes [13], and skeletal muscle [14].
3. Toll-Like Receptor Ligands and Antagonists
In addition to PAMPS, TLRs are stimulated by host-
derived molecules such as high mobility group box 1
protein (HMGB-1) [15]. TLRs achieve ligand specificity by
receptor dimerization: almost all the TLRs form homodimers
except TLR 1, 2, and 6 whilst TLR 2 can heterodimerise
with either TLR 1 or 6 depending upon the ligand that
is presented [16]. The exogenous TLR ligands can be
subdivided into 3 groups (Table 1). The first group consists
of lipids which are recognised by TLR 1, 2, 4, and 6, the
second group are proteins which bind to TLR 5 and 11,
and the third group consists of nucleic acids which activate
the intracellular TLRs such as TLR 3, 7, 8, and 9. Recent
studies have identified numerous host-derived ligands of
TLRs that are released under certain physiological and
pathophysiological conditions. These are also summarised in
Table 1, however particularly interesting endogenous ligands
are heat shock proteins (HSP) [17], hyaluronic acid [18],
and HMGB-1. These ligands are secreted in states of shock
or tissue injury and are therefore involved in activating
TLRs in certain pathological conditions such as hypoxia and
ischaemia.
The emerging importance of TLR activation in the
pathogenesis of numerous conditions has led to the devel-
opment of a number of synthetic TLR antagonists. So
far these antagonists are structural analogues of agonists
which prevent the stimulating ligand binding to the receptor
[19]. Disease modulation by TLR antagonism is not only
being studied in animal models but a number of clinical
trials in humans are underway for the treatment of septic
shock and autoimmune disorders. Nonetheless there are very
limited TLR antagonists available at present, and a better
understanding of TLR ligands will aid in the development of
a broader spectrum of antagonists. In this respect, various
groups are using screening techniques such as systemic
evolution of ligands by exponential enrichment (SELEX) and
high-throughput screening (HTS) to identify and develop
oligonucleotides and synthetic phospholipid compounds
with the potential to inhibit TLR signalling.
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Figure 1: TLR signalling pathway. MyD88-dependent signalling pathway is used by all TLRs except TLR 3. Signalling through the MyD88-
dependent pathway leads to the activation of MAPKK and IKK complex resulting in activation and nuclear translocation of AP-1 and NF-κB,
respectively. TLR 4 is capable of signalling through the MyD88-independent pathway as well; however this is the sole signalling mechanism
for TLR 3. TRIF is the main adaptor protein in the MyD88-independent pathway and can associate with TRAF6 to activate AP-1 and NF-κB.
Alternatively it also activates NF-κB by interacting with RIP-1. TRIF can further interact with TRAF3 and the phosphatidylinositol 3-kinase
(PI3K)-AKT pathway resulting in the nuclear translocation of IRF3 and IRF2, respectively.
4. TLR Signalling
Stimulation of TLRs upon ligand recognition leads to
the activation of its downstream signalling cascade which
culminates in the activation of the transcription factors,
nuclear factor-κB (NF-κB), and activator protein 1 (AP-
1). This results in the release of various proinflammatory
cytokines such as IL-6, IL-1, and TNF-α. The initiation
of this signalling cascade depends upon the binding of
the TIR domain of the intracellular portion of TLRs
to the TIR domain-containing cytosolic adapter proteins.
The four main adapter proteins are myeloid differentia-
tion primary response protein 88 (MyD88), TIR domain-
containing adapter protein (TIRAP/Mal), TIR domain-
containing adapter-inducing IFNβ (TRIF, also known as
TICAM1), and TRIF-related adapter molecule (TRAM, also
known as TICAM2) [20]. Also important for TLR signalling
transduction is the interleukin-1 receptor-associated kinase
(IRAK) family of which four members have so far be
identified: IRAK1, IRAK2, IRAK3, and IRAK-M. Two sepa-
rate signalling pathways exist for the signalling transduction
of TLRs: these are termed the MyD88-dependent pathway
of which MyD88 plays a central role and the MyD88-
independent pathway which uses TRIF instead. All TLRs
utilise theMyD88-dependent pathway except TLR3; interest-
ingly TLR4 is capable of using either signalling pathway.
In the MyD88-dependent pathway (Figure 1), ligand
binding leads to the association of MyD88 to the TIR
domain of the receptor. This leads to the phosphorylation
of IRAK4 which in turn phosphorylates IRAK1. IRAK1
binds to and activates tumour necrosis factor receptor-
associated factor 6 (TRAF6). The IRAK1/TRAF6 complex
dissociates from the intracellular receptor complex and
forms a complex with the E2 ligases Ubc13 and Uev1A
which have been shown to catalyse the synthesis of a Lys
63-linked polyubiquitin chain of TRAF6. This complex
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Table 2: Summary of the evidence for the role of TLRs in the pathogenesis of tissue damage in ischaemia and I/R injury.
Organ ischaemia
and I/R injury
Expression of TLRs
Upregulation of
TLRs in ischaemia
Evidence for role of TLR in
pathophysiology
Potential endogenous
ligand implicated in
pathogenesis
Cerebral
Glial cells: TLR 1–9 [32, 33]
Neurons: TLR 2 and 4 [34]
TLR 2, 4 and 9
[34, 35]
TLR 2 and 4 knockout mice have
reduced infarct size following
ischaemia [34, 36–38]
HSP 70 [34]
Liver
Hepatocytes: TLR 2, 3, 4
and 5 [39]
Non-parenchymal cells:
TLR 2, 3, 4, 5, 7 and 9 [39]
TLR 2 [40]
TLR 4 and 9 knockout mice are
protected against ischaemia-induced
liver injury [41–43]
HSP 72 [44] and
HMGB-1 [42, 45]
Renal
Parenchyma: TLRs 1–10 at
varying detection levels
[46–48]
TLR 2 and 4
[47, 49]
TLR 2 and 4 knockout mice are
protected against renal I/R injury, and
this is associated with a reduction in
inflammatory cytokine levels [49–52]
HMGB-1, hyaluronan
and biglycan
[49, 51, 53]
Myocardial
Myocytes: TLR 2, 3, 4 and 6
[54]
TLR 4 [55]
TLR 2- and 4-deficient mice show
reduced myocardial infarct size
[56–59]. TLR 4 antagonist eritoran
leads to reduced infarct size, NF-κB
nuclear translocation, and
proinflammatory cytokine expression
[60]
HMGB-1 [61]
Skeletal muscle TLR 1–9 [62–64] TLR 2, 4, 6 [65]
TLR 2 antagonsim reduces
pro-inflammatory cytokine expression
in an in vitro model of skeletal muscle
ischaemia [65]
Under investigation
further associates with a member of the MAP kinase kinase
kinase family, transforming growth factor-β-activated kinase
1 (TAK1) and the TAK1-binding proteins, TAB1 and TAB2.
This complex formation subsequently activates TAK1 which
simultaneously activates the IκB kinases (IKK) complex and
members of the MAP kinase family such as extracellular
signal-regulated kinase (ERK), c-Jun kinase (JNK), and p38.
The IKK complex consists of two kinases, IKKα and IKKβ
and a regulatory subunit (NEMO/IKKγ) [21]. IKK-activated
complex subsequently phosphorylates the inhibitory IκB
proteins which normally sequester NF-κB in an inactive
form in the cytoplasm. IκB protein phosphorylation leads
to their polyubiquitylation and subsequent degradation with
the concomitant release and nuclear translocation of NF-
κB. The activation of members of the MAPK family such as
JNK leads to the subsequent phosphorylation and activation
of the transcription factor AP-1. Further, stimulation of the
MyD88-dependent pathway in TLR 7, 8, and 9 can also lead
to the induction of type 1 interferons(IFN) possibly through
the activation of interferon regulatory factor 7 (IRF7) [22].
The MyD88-independent pathway which is the sole
signalling transduction system of TLR 3 and is an alternative
signalling pathway for TLR 4 also culminates in the activation
of NF-κB and AP-1 as well as IRF3 leading to the induction of
type 1 interferons. In theMyD88-independent pathway TRIF
is the main adaptor protein. In TLR 3 signalling TRIF binds
directly to the cytoplasmic portion of the receptor; however
in TLR 4 signalling the adaptor protein TRAM acts as a
bridge between TRIF and the TIR-containing domain. TRIF
can interact with TRAF6 or receptor-interacting protein-1
(RIP-1) leading to the activation of NF-κB and AP-1. Further
TRIF leads to the phosphorylation and the consequent
activation of IRF 3 and 7 leading to the induction of type
1 IFNs. Two members of the IKK family IKKi (IKKε) and
TBK1 [TRAF family member-associated NF-κB activator
(TANK) binding kinase-1 or T2K or NAK] are however
essential to this role [23, 24].
5. Ischaemia and Ischaemia/Reperfusion Injury
The pathophysiology of ischaemia and ischaemia/reperfu-
sion- (I/R-) induced injury has been extensively studied and
evaluated in various organ systems such as the kidneys, liver,
cardiovascular, and central nervous systems (CNS) (Table 2).
There is growing evidence that TLRs play an important
role in the propagation of the tissue damage caused by
ischaemia and I/R. However there is still a lack of significant
progress in understanding the pathophysiology of skeletal
muscle damage in CLI and the role TLRs play in this disease
process. Following ischaemia or I/R a number of cellular
and biochemical changes occur both locally and systemically.
This include the recruitment of activated neutrophils [25]
and lymphocytes [26], production of reactive oxygen species
(ROS), release of cytokines [27] and chemokines [28], and
activation of the complement system [29]. The generation
of ROS, ATP deletion, and activation of enzymes such as
phospholipases and proteases lead to cell necrosis. Apoptosis
has also been shown to occur following ischaemia [30],
and it is thought that mitochondrial dysfunction secondary
to ROS generation plays a role in inducing the apoptotic
mechanism. In addition, TLRs seem to play an important
role in mediating some of the ischaemia-induced injury.
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Endogenous ligands of TLRs such as fibrinogen, heparin
sulphate, hyaluronan, HSP60, HSP70, and HMGB-1 are
released by injured and necrotic cells. The subsequent
stimulation of TLRs by these ligands leads to the activation
of transcription factors NF-κB and AP-1 with a consequent
release of proinflammatory cytokines. Further TLRs have
been implicated in directly causing apoptosis via a pathway
involving Fas-associated death domain protein (FADD) and
caspase 8 [31].
6. The Role of Toll-Like Receptors in
the Pathophysiology of Cerebral Ischaemia
and I/R Injury
There is emerging evidence that TLRs play a role in neuronal
damage secondary to cerebral ischaemia. TLRs are thought
to be expressed primarily by the glial cells (microglia,
astrocytes, and oligodendrocytes) in the brain. Human
microglia are found to express TLRs 1–8 at detectable levels
and TLR 9 at low but detectable levels [32]. The expression of
TLRs in human astrocytes, however, is more restricted with
only TLR 3 mRNA detected at intermediate levels; mRNA
for TLRs 1, 2, 4, 5, and 9 were detectable but were low,
and TLRs 6, 7, 8, and 10 mRNA expression was found to
be rare to undetectable [33]. Very little is known about the
expression of TLRs in human oligodendrocytes, but Bsibsi et
al. [32] have reported expression of TLRs 2 and 3 in these
cells. TLRs 2 and 4 have also been found to be expressed in
mouse cerebral cortical neurons [34]. When microglia and
astrocytes are exposed to TLR ligands such as peptidoglycan,
double-stranded RNA, lipopolysaccharide, and bacterial
DNA there is a release of a wide range of proinflammatory
cytokines (including TNF-α, IL-6, and IL-12), chemokines,
and reactive oxygen species. This suggests that the TLRs are
involved in protecting the CNS against microbial infections,
although it is unclear whether this neuroinflammatory
response is beneficial or detrimental. Growing evidence
suggests that the TLRs expressed in the CNS also play an
important role in tissue development, cellular migration and
differentiation, and in limiting inflammation [66].
Acute inflammation exacerbates brain damage in cere-
bral ischaemia, and activation of the innate immune system
is an important component of this process. There is now
strong evidence suggesting that TLRs within the CNS play an
integral part in this inflammatory process. For example TLRs
2, 4, and 9 have been shown to be upregulated and activated
in cerebral ischaemia models [34, 35]. Significantly a number
of groups have reported reduced infarct size in TLR 2 and 4
knockout mice that have been exposed to cerebral ischaemia
[34, 36–38]. Kilic et al. [36] performed intraluminal middle
cerebral artery occlusion as a model of ischaemic stroke in
adult male C3H/HEJ TLR 4 knockout mice. They showed
that in the TLR4-deficient mice there was reduced ischaemic
neuronal injury, and the mechanism of this neuroprotective
effect was associated with deactivation of the MAP kinases
ERK 1, ERK2, JNK1, JNK2, and P38 [36]. Further, Caso et
al. [67] not only demonstrated reduced infarct size but also
recovery of neurological deficit in TLR 4 knockout mice that
had MCA occlusion suggesting actual clinical improvement
as a result of abolishing the effects of TLR 4. Interestingly,
studies have shown that LPS (TLR 4 ligand) pre-conditioning
helps to protect against subsequent ischaemic damage;
however the mechanism for this is unclear. Thus, there is
now significant evidence that TLRs in particular TLR 2
and 4 play a role in ischaemia-induced cerebral damage
but the exact mechanisms are yet to be elucidated. Apart
from the increase in proinflammatory cytokines, activated
glial TLRs also lead to the release of chemokines such as
macrophage inflammatory protein-2 (MIP-2) and monocyte
chemoattractant protein-1 (MCP-1) which attract peripheral
immune cells into the brain parenchyma and may lead to
further exacerbation of ischaemic damage. Using a model of
glucose deprivation as a form of energy deprivation, Tang et
al. [34] found that TLR2 and 4 are implicated in apoptotic
neuronal cell death via activation of the JNK-AP-1 pathway.
In addition they showed that the endogenous ligand of TLR
2 and 4, HSP70, is upregulated thus implicating HSP70 and
other endogenous ligands of TLRs in the pathogenesis of
cerebral ischaemia.
7. The Role of Toll-Like Receptors in
the Pathophysiology of Liver Ischaemia
and I/R Injury
Liver ischaemia and reperfusion can occur during a variety
of situations particularly during surgical procedures such
as liver transplant, vascular reconstruction, liver trauma,
and resection of large hepatic tumours. During the initial
ischaemic period a certain level of cellular damage has been
shown to occur [68]; however this is further exacerbated
following reperfusion [69]. The liver is primarily composed
of parenchymal cells (hepatocytes) constituting 65% of
the cells in the liver. The remaining part of the liver is
composed of nonparenchymal cells such as kupffer cells,
sinusoidal endothelial cells, biliary epithelial cells, hepatic
stellate, and dendritic cells. Studies have shown that both
the parenchymal and nonparenchymal cells express a large
repertoire of TLRs [39].
Kupffer cells which are the resident macrophages of the
liver play a central role in hepatic I/R injury. Following
hepatic ischaemia kupffer cells are activated and lead to
the release of both proinflammatory cytokines (TNF-α,
IL-6, and IL-1) as well as anti-inflammatory cytokines
(IL-10 and IL-13) and ROS [70]. Inflammatory cytokines
both initiate and maintain the inflammatory response and,
together with the activated complement system, result in the
migration and adhesion of leukocytes and recruitment of
neutrophils within the sinusoids [71]. Activated neutrophils
further exacerbate liver damage induced by reperfusion,
through the release of more ROS and proteases [72]. The
resulting increase in ROS causes oxidative stress and cell
death. Significantly, ROS especially hydrogen peroxide [73]
activate NF-κB which has been found to play a significant
role in liver I/R injury [74]. Cell death in liver I/R has
been shown to occur by both apoptosis [75] and necrosis
[76]. Inflammatory mediators such as TNF-α released by
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kupffer cells and neutrophils have been shown to activate
pro-apoptotic proteins such as caspase-3 and caspase-8
further highlighting the role of these cells in ischaemic liver
damage [77].
Several groups have illustrated the importance of TLR
signalling in hepatic I/R damage [40–42, 45]. In particular
TLR 4 and 9 are specifically implicated in the pathological
process. Tsung et al. [41] showed that chimeric mice lacking
functional TLR 4 subjected to liver I/R were protected from
tissue damage. Further they showed that this protective
effect was associated with a reduction in the activation of
JNK and NF-κB as well as a decrease in the expression of
the proinflammatory cytokines TNF-α and IL-6 and the
adhesion molecule ICAM-1. Shen et al. [43] also showed
that TLR 4 knockout mice were protected against hepatic
I/R injury, and this was associated with a reduction in local
and systemic TNF-α levels as well as reduced neutrophil
infiltration.
Circulating levels of HSP72 have shown to be increased
during hepatic I/R injury [44, 78]. HSP72 stimulated both
TLR 2 and 4 in hepatocytes leading to the activation
of NF-κB and the subsequent production of macrophage
inflammatory protein-2 (MIP-2) but not TNF-α or IL-6.
MIP-2 promotes neutrophil infiltration during hepatic I/R
injury, and blockade of MIP-2 has been shown to reduce
hepatic I/R injury [79]. In TLR 2 and 4 knockout mice, MIP-
2 production is reduced suggesting that both TLR 2 and 4
contribute to hepatic I/R injury [78]. However, despite an
increase in TLR 2 mRNA levels after hepatic I/R injury [40]
it has been found that TLR 4 but not TLR 2 is required in
initiating the hepatic injury cascade as it was demonstrated
that TLR 2 knockout mice and wild-type mice livers suffered
comparable I/R injury [80]. Further, Zhai et al. [80] have
suggested that TLR 4-induced hepatic damage in I/R is
mediated through the MyD88-independent pathway rather
than the MyD88-dependant pathway. They showed that IRF
3-deficient mice protected their livers from I/R injury in
a similar fashion to TLR 4-deficient mice but in MyD88-
deficient mice significant hepatic I/R injury still occurred.
This finding however cannot account for the increase in
the proinflammatory cytokines which occurs during liver
ischaemia and may be explained by the work carried out
by Bamboat et al. [42] demonstrating that TLR 9 may
also be involved in hepatic I/R injury. They reported that
following I/R TLR 9 knockout mice showed minimal hepatic
damage associated with reduced proinflammatory cytokine
levels (TNF-α, IL-6, and MCP-1) compared to wild-type
mice which exhibited severe hepatocellular necrosis. TLR
9 blockade also reduced liver damage and cytokine levels
in wild-type mice that were subjected to I/R. This suggests
that both TLR 4 and 9 play an important role in hepatic
damage secondary to ischaemia and I/R injury and that TLR
9 stimulation may mediate the increase in proinflammatory
cytokines.
In addition to HSP72, other endogenous TLR ligands
may be involved in hepatic I/R. Bamboat et al. [42] have
shown that DNA from necrotic hepatocytes stimulate TLR
9 leading to cytokine release. HMGB-1 is a DNA-binding
protein which is released by necrotic cells including
hepatocytes. HMGB-1 levels increase during liver I/R, and
inhibition of HMGB-1 with a neutralising antibody reduces
liver damage after I/R [42, 45]. Thus, numerous TLR
endogenous ligands have been implicated in hepatic I/R
injury; however it remains to be seen howmuch each of them
contributes to hepatic I/R injury.
8. The Role of Toll-Like Receptors in
the Pathophysiology of Renal Ischaemia
and I/R Injury
Renal ischaemia and I/R injury can occur during trans-
plantation, partial nephrectomy, aortic cross-clamping, and
following systemic hypotension and is a common cause of
acute renal failure (ARF). The pathogenesis of ischaemia
and I/R-induced renal injury is complex and incompletely
understood. However, it is not surprising that the innate
immune system plays a significant role in the injury
process. Ischaemia leads to the depletion of cellular ATP,
and this causes tubular epithelial cells to undergo necrosis
or apoptosis [81]. In addition to the cytotoxic effects of
hypoxia, I/R triggers numerous inflammatory events. The
renal endothelial and epithelial cells release inflammatory
cytokines (IL-1, IL-6 and TNF-α) [82] as well as chemokines
and express adhesion molecules that activate lymphocytes.
Further, the infiltrating leukocytes also generate cytokines
and ROS that exacerbate cellular injury. Several studies
have also highlighted the importance of activation of the
complement system [83], neutrophils [84], B cells [85], and
T cells [86] in the development of renal I/R injury.
TLR expression in the kidney has been studied by several
groups andmRNA for almost all the TLRs have been detected
in human kidneys [46–48]. However TLRs 1, 2, 3, 4, 5, and
7 were found to be more abundantly expressed than TLRs
6, 8, 9, and 10. TLR 2 and 4 are expressed in mouse renal
cortex and medulla, specifically in the proximal and distal
tubules as well as in the epithelium of Bowman’s capsule
[47]. Recent studies have implicated TLR 2 and 4 in the
pathogenesis of renal ischaemia and I/R injury. It has been
shown that TLR 2 and 4 mRNA is upregulated following
I/R in the epithelial cells of the distal tubules, thin limb of
the loops of Henle, and collecting ducts. This upregulation
was shown to be mediated by IFN-γ and TNF-α [47]. It
has been found that TLR 2 knockout mice are protected
against renal I/R injury [50, 51]. Leemans et al. [51] used
TLR 2 antisense oligonucleotide treatment to reduce TLR 2
protein in mice kidney and showed that this also protected
the kidney against I/R injury by demonstrating reduced renal
dysfunction. The detrimental effects of TLR 2 signalling in
renal I/R injury were observed to be due to an increase
in chemokine and cytokine (MIP-2, TNF-α, IL-6, IL-1β)
production, granulocyte andmacrophage infiltration, as well
as tubular necrosis, and tubular epithelial cell apoptosis,
which was mediated through nonhematopoietic cells of the
kidney. Interestingly Shigeoka et al. [87] have suggested a
fascinating concept that renal damage in I/R due to TLR
2 activation is mediated through both a MyD88-dependent
pathway as well as a TLR 2-dependent/MyD88-independent
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pathway.TLR 4 has also been shown to play a significant
role in renal I/R injury. Wu et al. [49] have demonstrated
increased TLR 4 expression following kidney ischaemia. As
demonstrated in TLR 2 knockout mice, it has also been
shown that TLR 4 knockout mice are protected against renal
dysfunction following I/R injury [49, 50, 52]. Further TLR
4 knockout mice subjected to I/R showed reduced tubular
damage, neutrophil and macrophage accumulation, and
inflammatory cytokine and chemokine production. In vitro,
wild-type kidney tubular epithelial cells (TECs) that were
subjected to ischaemia produced inflammatory cytokines
and chemokines and underwent apoptosis. These effects
were attenuated in TLR4−/− andMyD88−/− TECs [49]. These
results provide significant evidence for the role of TLR 2
and 4 in the pathogenesis of ischaemia and I/R-mediated
renal damage. A number of studies have demonstrated an
upregulation of several TLR 2 and 4 endogenous ligands
such as HMGB-1, hyaluronan and biglycan in the kidney
during I/R injury [49, 51, 53] which may be involved in the
activation of these receptors and subsequent inflammatory
response and tissue damage in renal I/R.
9. The Role of Toll-Like Receptors in
the Pathophysiology of Myocardial
Ischaemia and I/R Injury
Myocardial ischaemia is most commonly due to occlusion
of a major coronary artery. Coronary artery occlusion
and the consequent reduction in blood flow usually occur
due to fissuring or erosion of an atherosclerotic plaque
with subsequent formation of thrombus. The pathogenesis
of ischaemia-induced myocardial damage has been inten-
sively studied, and a number of biochemical and cellu-
lar mechanisms have been discovered. Oxygen deficiency
induces metabolic changes such as decreased ATP and pH
as well as lactate accumulation. The altered biochemical
status leads to impaired membrane transport resulting in
an imbalance in intracellular electrolytes and propagates
various other pathological metabolic changes resulting
in cardiomyocyte death through necrosis and apoptosis.
Irreversible damage occurs after approximately 30 min-
utes of coronary artery occlusion. Reperfusion exacerbates
myocardial damage which is predominantly the effect of
oxygen radicals, calcium loading, and neutrophil activation.
Oxygen radicals cause further membrane damage, and neu-
trophils release inflammatory mediators and contribute to
microvascular obstruction [88–90]. Inflammatory cytokines
such as IL-6, TNF-α, IL-1β, and IL-8 have been shown
to be upregulated during periods of myocardial ischaemia
[91–93].
Most of the TLRs are expressed within the cardiovascular
system. In particular, TLR 2, 3, 4, and 6 are expressed in
rat cardiomyocytes [94] whilst both healthy and atheroscle-
rotic arteries express TLRs 1–9 [55]. TLR 2 and 4 have
been strongly implicated in myocardial damage following
ischaemia and reperfusion. Murine TLR 4 expression has
been shown to be increased after myocardial infarction
[56], and various studies have shown that TLR 4-deficient
mice have reduced myocardial infarct size when compared
with control mice [57, 58, 95]. Studies have shown that
the reduction in myocardial infarct size in TLR 4-deficient
mice is attributed to a reduction in neutrophil infiltration
and reduced JNK, NF-κB, and AP-1 activation with a
subsequent decrease in the levels of inflammatory cytokines
(IL-1β and Il-6) and monocyte chemotactic factor-1 [57,
60, 95]. The P13K/AKT pathway has also been reported
to play a role in protecting against myocardial I/R injury
in TLR 4-deficient mice [96]. Mice pretreated with the
TLR 4 antagonist eritoran prior to transient occlusion of
the left anterior descending artery were shown to develop
significantly smaller infarcts compared to mice treated with
vehicle alone. Further, eritoran pretreatment resulted in
reduced JNK phosphorylation, NF-κB nuclear translocation,
and proinflammatory cytokine expression [59].
There is also emerging evidence for the role of TLR 2
in myocardial I/R Injury. TLR 2 knockout mice subjected
to myocardial infarction have been shown to have a higher
survival rate than wild-type mice associated with a smaller
infarct size, reduced ROS production, and leukocyte infil-
tration [97, 98]. Further, both bone marrow chimeric mice
developed by transplanting TLR 2 knockout bone marrow
to WT mice or WT bone marrow to TLR 2 knockout mice
submitted to I/R 5 weeks after transplant displayed similar
protection as TLR2−/− mice against I/R-induced endothelial
dysfunction, suggesting a role for TLR 2 expressed on both
non-bone marrow cells such as endothelial cells and/or
cardiomyocytes and cells of bone marrow origin such as
neutrophils [98]. TLR 2 deficiency also abolished increased
IL-1β expression but did not affect TNF-α or IL-6 expression.
These studies provide some insight into the role of TLR 2
and 4 in myocardial I/R injury and may reveal potential
therapeutic targets.
HMBG-1 may again act as an endogenous TLR ligand
in myocardial ischaemia. Andrassy et al. [99] demonstrated
elevated levels of HMGB-1 following hypoxia in cardiomy-
ocytes in vitro and in ischaemic injury of the heart in
vivo. They also reported that treatment with recombinant
HMGB-1 worsens I/R injury, whereas treatment with the
HMGB-1 antagonist HMGB-1 box A reduced infarct size and
markers of tissue damage. In addition their data suggested
that HMGB-1-mediated myocardial damage involved JNK,
ERK 1 and 2, and NF-κB activation. Several other known
HMGB-1-inhibiting agents (ethyl pyruvate, green tea, and
adrenomedullin) have also been shown to preserve cardiac
function following a myocardial ischaemic insult [54, 100,
101]. Further studies may reveal the involvement of other
potential endogenous ligands in the setting of myocardial
ischaemia.
10. The Potential Role of Toll-Like
Receptors in the Pathophysiology of
Critical Limb Ischaemia
CLI is a severe form of PAD that is predominantly caused by
atherosclerosis in the peripheral arterial system. Whilst the
detailed pathophysiology of CLI is not well understood, there
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is a basic understanding of the pathogenesis of skeletal mus-
cle damage in peripheral arterial disease (PAD) and in I/R
injury. A large proportion of mass in the limb is comprised
of skeletal muscle, and therefore it is affected significantly by
ischaemia-induced tissue damage. Studies have shown that
irreversible muscle damage begins to occur after 3 hours
of ischaemia and is nearly complete after 6 hours [102].
Pipinos et al. [103] have proposed a potential pathway for
the pathogenesis of PAD-induced manifestations such as
skeletal muscle damage and tissue loss, where inflammation,
neutrophil activation and degranulation, and mitochondrial
dysfunction with excessive production of ROS occur when
blood supply is critically compromised. The consequences
of these pathological processes include reduced energy
production and damage to muscle as well nerves, skin, and
subcutaneous tissue. Indeed, Hayes et al. [104] found that
after a sustained period of ischaemia, diminishing ATP levels
correlated closely with worsening muscle necrosis. Further,
gastrocnemius muscle biopsies obtained from patients with
PAD contain a higher number of apoptotic cells com-
pared to controls as shown by Terminal Deoxynucleotidyl
Transferase Biotin-dUTP Nick-end Labelling- (TUNEL-)
staining and increased Caspase-3 activity [105]. Raised
circulating levels of proinflammatory cytokines (TNF-α;
14.48 ng/ml versus 9.32 ng/ml and IL-6; 11.81 ng/ml versus
7.30 ng/ml), chemokines (vascular cell adhesion molecule-
1 (VCAM-1); 485.09 ng/ml versus 464.35 ng/ml, and inter-
cellular adhesion molecule-1 (ICAM-1); 316.7 ng/ml versus
207.65 ng/ml) are found in the plasma of patients with
PAD [106]. Significantly, TNF-α and IL-6 have been shown
to induce muscle proteolysis, and this in turn has been
associated with reduced muscle mass and strength [62, 107,
108]. In addition TNF-α has also been reported to induce
apoptosis in skeletal myoblasts [63]. It is therefore possible
that the elevated levels of cytokines play a role in skeletal
muscle damage in CLI.
TLRs 1–9 have been shown to be expressed in skeletal
muscle [61, 64, 109]. Further, there is evidence to suggest
that some of the TLRs are functional as lipopolysaccharide
(LPS) and a synthetic tripalmitoylated cysteine-, serine-,
and lysine-containing peptide (Pam), TLR 4, and TLR 2
ligands, respectively, induce TNF-α, IL-6, and IL-1β mRNA
expression in gastrocnemius muscle and C2C12 myotubes
[64, 109]. Further IL-6 induction has been shown to be
mediated via activation of NF-κB [62]. Warren et al. [61]
demonstrated that TLRs 2, 4, 6, 8, and 9 are upregu-
lated following freeze-induced skeletal muscle damage. TLR
endogenous ligands such as HMGB-1 and HSPs have been
shown to be expressed in skeletal muscle. HMGB-1 has been
reported to induce skeletal muscle damage in inflammatory
myopathies, and the expression of HSPs is upregulated
in skeletal muscle following hypoxia and ATP depletion
[110, 111]. We have recently found upregulation of TLRs
2, 4, and 6 protein expression in muscle biopsies obtained
from patients with CLI (Figure 2). This indicates that TLRs
are likely to be involved in the pathophysiology of CLI,
possibly by contributing to the tissue damage that occurs,
and provides the rationale to further elucidate the role of
TLRs in the pathogenesis of skeletal muscle damage in CLI.
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Figure 2: Representative western blots showing (a) increased TLR
2, TLR 4, and TLR 6 protein expression in gastrocnemius muscle
biopsies obtained from patients with CLI compared to controls.
(b) Densitometric quantification of TLR 2, 4, and 6 levels in CLI
muscle. ∗P < 0.05 compared to control. The human experiments
were conducted in accordance with the Declaration of Helsinki
(1964), and informed consent was obtained from patients with
prior approval from the local ethics committee.
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Figure 3: Proposed pathophysiological mechanism of skeletal muscle damage in CLI. Skeletal muscle ischaemia initiates muscle cell
apoptosis and necrosis leading to the release of endogenous ligands such as HMGB-1. Subsequently TLRs are activated in other viable
muscle cells causing signalling through one or more TLR signalling pathways. This may lead to the activation of transcription factors such
as NF-κB, AP-1, IRF 3, and 2. The consequent activation of transcription factors leads to the induction and release of proinflammatory
cytokines, chemokines, and interferons that propagate the skeletal muscle damage.
11. Conclusion
It can be concluded that following ischaemia and I/R signif-
icant tissue damage occurs in a number of different organs.
The intricate mechanisms involved may differ depending on
the type and duration of insult. However it is clear that
inflammation following immune cell infiltration and ROS
generation play a significant role in mediating cytotoxicity.
There is ample evidence that TLRs of both immune and
nonimmune cell origin are upregulated and activated in
ischaemia leading to the production of various proinflamma-
tory cytokines and chemokines. Both the MyD88-dependent
and MyD88-independent TLR signalling pathways may be
involved in mediating the ischaemic tissue damage, and the
dominant signalling cascade used may be organ specific.
TLRs have also been implicated in apoptotic cell death which
plays a large part in ischaemia-induced cell damage. Necrotic
cell death has also been shown to occur following ischaemia,
and this is important as numerous TLR endogenous ligands
such as HSP60 and HMGB-1 have been shown to be
released during this process. This phenomenon may explain
why TLRs are activated in sterile inflammation during
ischaemia and provide an opportunity to manipulate the
pathophysiological process in order to reduce cell damage.
There is growing evidence to suggest that some of these
destructive processes are involved in the pathophysiology of
skeletal muscle damage in CLI, and TLRs are implicated
in mediating this damage. However, further studies are
required to elaborate on the preliminary data including the
identification of the key TLRs involved in mediating skeletal
muscle damage in CLI (Figure 3). One can speculate that
TLR 2 and TLR 4 may be important as there is extensive data
on the role of these two receptors in mediating ischaemic
and I/R injury. However, other TLRs such as TLR 1 and 6
are promising targets as they are known to heterodimerise
with TLR 2 [16]. It would also be essential to identify
the particular TLR signalling pathways and transcription
factors involved in ischaemic skeletal muscle. Further TLR
antagonists are under clinical development in the treatment
of a number of inflammatory and autoimmune diseases
[19], and TLR antagonists have also been shown to reduce
ischaemia-induced injury. A better understanding of the
pathophysiology of CLI with concomitant development of
TLR antagonists may identify treatment modalities that can
be translated into clinical benefit for patients with CLI.
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